Selvita

Selvita EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Selvita (SLV.WA) as of Oct 21, 2026 is 16.42. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 21.84 — a change of -24.81% (lower).

EV/FCF

16.42

YoY

-24.81%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Selvita is 2025 16.42 . EV/FCF (Enterprise Value to Free Cash Flow) of Selvita was 2024 21.84 . It decreases by -24.81% lower compared to the previous year.

The Selvita EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
203.05 PLN
Jan 1, 2019
261.70 PLN
Jan 1, 2020
51.06 PLN
Jan 1, 2021
14.64 PLN
Jan 1, 2022
-35.62 PLN
Jan 1, 2023
191.55 PLN
Jan 1, 2024
21.84 PLN
Jan 1, 2025
16.42 PLN
The Selvita EV/FCF history
YEAREV/FCFYoY
16.42-24.81%
21.84-88.60%
191.55-637.82%
-35.62-343.28%
14.64-71.33%
51.06-80.49%
261.70+28.88%
203.05+134.45%
86.61-407.12%
-28.20-20.47%
-35.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Selvita Stock analysis

What does Selvita do? Selvita SA generates revenue through multidisciplinary solutions for drug discovery, regulatory studies, and research and development. The company provides early-stage drug discovery support, including target validation and clinical candidate selection, alongside drug testing and bioanalytical services such as method development, stability studies, and quality control testing. Its clients include pharmaceutical companies and research institutions across Europe and the United States, which rely on Selvita's expertise for comprehensive project support throughout the drug development lifecycle. The firm's services span the entire drug discovery process, from initial target identification to preclinical research and clinical candidate selection. By offering end-to-end solutions, Selvita caters to clients seeking efficient and reliable support in complex research phases. Its collaborations with European and American research institutes and universities further strengthen its position in the biotech and pharmaceutical sectors. Selvita SA's business model focuses on delivering specialized scientific services tailored to the needs of clients in drug development. The company's offerings cover all critical stages of the drug discovery process, ensuring clients can advance their projects with minimal delays. This approach allows Selvita to maintain strong relationships with its key clients in the pharmaceutical and research communities. Selvita is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Selvita stock

EV/FCF (Enterprise Value to Free Cash Flow) of Selvita is 16.42 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Selvita changed from 21.84 to 16.42, representing a -24.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Selvita since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Selvita with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Selvita

All Key Metrics — Selvita